CXCL13 and COVID-19: We studied well-known markers of antiviral immunity including antibody production to the SARS-CoV-2 receptor binding domain (RBD), nucleocapsid (N), and spike s1 (S1) protein domains; Th1- and Th2-associated cytokine production; and CXCL13 production to characterize the immune profile of COVID-19 patients.